108 related articles for article (PubMed ID: 21970686)
1. Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2.
Yang LP; Zhou ZW; Chen XW; Li CG; Sneed KB; Liang J; Zhou SF
Xenobiotica; 2012 Mar; 42(3):238-55. PubMed ID: 21970686
[TBL] [Abstract][Full Text] [Related]
2. [Modeling of a three-dimensional structure of cytochrome P-450 1A2 and search for its new ligands].
Belkina NV; Skvortsov VS; Ivanov AS; Archakov AI
Vopr Med Khim; 1998; 44(5):464-73. PubMed ID: 9916262
[TBL] [Abstract][Full Text] [Related]
3. Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein.
Shimada H; Eto M; Ohtaguro M; Ohtsubo M; Mizukami Y; Ide T; Imamura Y
J Biochem Mol Toxicol; 2010; 24(4):230-4. PubMed ID: 20806393
[TBL] [Abstract][Full Text] [Related]
4. A pharmacophore model specific to active site of CYP1A2 with a novel molecular modeling explorer and CoMFA.
Zhang T; Wei DQ; Chou KC
Med Chem; 2012 Mar; 8(2):198-207. PubMed ID: 22385179
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibition of CYP1A2 by Frutinone A, an active ingredient of the broad spectrum antimicrobial herbal extract from P. fruticosa.
Thelingwani RS; Dhansay K; Smith P; Chibale K; Masimirembwa CM
Xenobiotica; 2012 Oct; 42(10):989-1000. PubMed ID: 22533317
[TBL] [Abstract][Full Text] [Related]
6. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.
Zhou SF; Wang B; Yang LP; Liu JP
Drug Metab Rev; 2010 May; 42(2):268-354. PubMed ID: 19961320
[TBL] [Abstract][Full Text] [Related]
7. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.
Wang B; Zhou SF
Curr Med Chem; 2009; 16(31):4066-218. PubMed ID: 19754423
[TBL] [Abstract][Full Text] [Related]
8. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.
Korhonen LE; Rahnasto M; Mähönen NJ; Wittekindt C; Poso A; Juvonen RO; Raunio H
J Med Chem; 2005 Jun; 48(11):3808-15. PubMed ID: 15916432
[TBL] [Abstract][Full Text] [Related]
9. A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries.
Chohan KK; Paine SW; Mistry J; Barton P; Davis AM
J Med Chem; 2005 Aug; 48(16):5154-61. PubMed ID: 16078835
[TBL] [Abstract][Full Text] [Related]
10. Heterologous expression and characterization of wild-type human cytochrome P450 1A2 without conventional N-terminal modification in Escherichia coli.
Kim DH; Kim KH; Isin EM; Guengerich FP; Chae HZ; Ahn T; Yun CH
Protein Expr Purif; 2008 Feb; 57(2):188-200. PubMed ID: 18032064
[TBL] [Abstract][Full Text] [Related]
11. Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations.
He L; He F; Bi H; Li J; Zeng S; Luo HB; Huang M
Bioorg Med Chem Lett; 2010 Oct; 20(20):6008-12. PubMed ID: 20832301
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study.
Paxton JW; Kestell P; Chiang D; Zhou S; Lewis DF
Clin Exp Pharmacol Physiol; 2005 Aug; 32(8):633-9. PubMed ID: 16120190
[TBL] [Abstract][Full Text] [Related]
13. Novel natural inhibitors of CYP1A2 identified by in silico and in vitro screening.
Zhu R; Hu L; Li H; Su J; Cao Z; Zhang W
Int J Mol Sci; 2011; 12(5):3250-62. PubMed ID: 21686183
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide.
Wei X; Dai R; Zhai S; Thummel KE; Friedman FK; Vestal RE
J Pharmacol Exp Ther; 1999 May; 289(2):853-8. PubMed ID: 10215663
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening and prediction of site of metabolism for cytochrome P450 1A2 ligands.
Vasanthanathan P; Hritz J; Taboureau O; Olsen L; Jørgensen FS; Vermeulen NP; Oostenbrink C
J Chem Inf Model; 2009 Jan; 49(1):43-52. PubMed ID: 19099399
[TBL] [Abstract][Full Text] [Related]
16. Development of a whole-cell screening system for evaluation of the human CYP1A2-mediated metabolism.
Chu CC; Pan KL; Yao HT; Hsu JT
Biotechnol Bioeng; 2011 Dec; 108(12):2932-40. PubMed ID: 21755496
[TBL] [Abstract][Full Text] [Related]
17. Computational prediction of binding affinity for CYP1A2-ligand complexes using empirical free energy calculations.
Vasanthanathan P; Olsen L; Jørgensen FS; Vermeulen NP; Oostenbrink C
Drug Metab Dispos; 2010 Aug; 38(8):1347-54. PubMed ID: 20413725
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning and functional analysis of cytochrome P450 1A2 from Japanese monkey liver: comparison with marmoset cytochrome P450 1A2.
Narimatsu S; Oda M; Hichiya H; Isobe T; Asaoka K; Hanioka N; Yamano S; Shinoda S; Yamamoto S
Chem Biol Interact; 2005 Feb; 152(1):1-12. PubMed ID: 15766918
[TBL] [Abstract][Full Text] [Related]
19. Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of alpha-glucosidase inhibitors.
Bharatham K; Bharatham N; Park KH; Lee KW
J Mol Graph Model; 2008 Jun; 26(8):1202-12. PubMed ID: 18096420
[TBL] [Abstract][Full Text] [Related]
20. In vitro effect of important herbal active constituents on human cytochrome P450 1A2 (CYP1A2) activity.
Pan Y; Tiong KH; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Ong CE
Phytomedicine; 2014 Oct; 21(12):1645-50. PubMed ID: 25442272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
